Azenta, Inc.
Close on Oct 19, 2026
- Market cap
- $1.58B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 20, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | After market close | $161.00M | $-0.03 | $0.16 |
| Q2 FY2026 Ended Mar 31, 2026 | May 5, 2026 | After market close | $145.00M | $-3.49 | $-0.04 |
| Q1 FY2026 Ended Dec 31, 2025 | Feb 4, 2026 | Before market open | $149.00M | $-0.11 | $0.09 |
| Q4 FY2025 Ended Sep 30, 2025 | Nov 21, 2025 | Before market open | $159.00M | $1.11 | $0.21 |
| Q3 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $144.00M | $-1.15 | $0.19 |
| Q2 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | $143.00M | $-0.40 | $0.05 |
| Q1 FY2025 Ended Dec 31, 2024 | Feb 5, 2025 | Before market open | $148.00M | $-0.29 | $0.08 |
| Q4 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $170.00M | $-0.10 | $0.18 |
| Q3 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | $173.00M | $-0.12 | $0.16 |
| Q2 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Dec 31, 2023 | Feb 7, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | Fourth Quarter Fiscal 2026 | $20.00M to $23.00M | New |
| Adjusted EBITDAnon-GAAP | Full Year Fiscal 2026 | $59.00M to $62.00M | New |
| Free cash flownon-GAAP | Full Year Fiscal 2026 | 10% to 15% growth | Maintained |
| total reported revenue from continuing operations | fiscal year ending September 30, 2026 | $613.00M to $618.00M | Narrowed |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Azenta filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.
Results of operations · EX-99.1 to Form 8-K
Azenta Completes Sale of B Medical Systems
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Basis of Unaudited Proforma Condensed Consolidated Financial Information
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026 , Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029
Results of operations · EX-99.1 to Form 8-K
Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Azenta Reports First Quarter Results for Fiscal 2026 , Ended December 31, 2025
Results of operations · EX-99.1 to Form 8-K
Azenta Enters Definitive Agreement for the Sale of its B Medical Systems Business to THELEMA S. À R.L.
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Azenta Authorizes $250 Million Share Repurchase Program
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Azenta Reports Fourth Quarter and Full Year Fiscal 2025 Results, Ended September 30, 2025
Results of operations · EX-99.1 to Form 8-K
Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025 ; Reiterates Full Year Fiscal 2025 Guidance
Results of operations · EX-99.1 to Form 8-K
Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025
Results of operations · EX-99.1 to Form 8-K
Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024
Results of operations · Shareholder vote results · EX-99.1 to Form 8-K
Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Azenta Reports Third Quarter Results for Fiscal 2024, Ended June 30, 2024
Results of operations · EX-99.1 to Form 8-K
Azenta Announces CEO Succession Plan
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Azenta Reports Second Quarter Results for Fiscal 2024, Ended March 31, 2024
Results of operations · EX-99.1 to Form 8-K
© 2024 Azenta, Inc. All rights reserved
Regulation FD disclosure · EX-99.1 to Form 8-K
Azenta Reports First Quarter Results for Fiscal 2024, Ended December 31, 2023
Results of operations · EX-99.1 to Form 8-K
Revenue from Continuing Operations – Fiscal 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Azenta Reports Fourth Quarter and Full Year Fiscal 2023 Results, Ended September 30, 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Azenta Announces Actions to Support Ongoing Strategic and Governance Transformation
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Industry Veteran Herman Cueto Named CFO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Azenta Reports Results of Third Quarter of Fiscal 2023, Ended June 30, 2023
Results of operations · EX-99.1 to Form 8-K
Azenta Reports Results of Second Quarter of Fiscal 2023 and Announces Business Realignment
Results of operations · EX-99.1 to Form 8-K
Azenta Reports First Quarter Results For Fiscal 2023, Ended December 31, 2022
Results of operations · EX-99.1 to Form 8-K
Azenta Life Sciences | Proprietary and confidential.
Results of operations · EX-99.2 to Form 8-K
Azenta Announces $500 Million Accelerated Share Repurchase Agreement
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Azenta Reports Fourth Quarter and Full Year Fiscal 2022 Results, Authorizes $1.5 Billion Share Repurchase Program
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Azenta Announces Agreement to Acquire B Medical Systems
Material agreement · Other events · EX-99.1 to Form 8-K
Azenta Life Sciences Reports Results of Third Quarter of Fiscal 2022, Ended June 30, 2022
Results of operations · EX-99.1 to Form 8-K
Azenta Reports Preliminary Results for Third Quarter of Fiscal 2022, Ended June 30, 2022 and Announces Earnings Conference Call and Webcast
Results of operations · EX-99.1 to Form 8-K
Azenta Announces Agreement to Acquire Barkey Holding GmbH
Material agreement · Other events · EX-99.1 to Form 8-K
Azenta Life Sciences Reports Preliminary Results of Second Quarter of Fiscal 2022, Ended March 31, 2022
Results of operations · EX-99.1 to Form 8-K